Antiproliferative Potential of Ethyl acetate Extract of Clerodendrum thomsoniae Balf.f. on DMBA-induced Breast Cancer in Female Sprague-dawley Rats
By: Muhammed Ashraf V. K
.
Contributor(s): Kalaichelvan, V. K.
Publisher: Karnataka Association of Pharmaceutical Teachers of India (APTI) 2021Edition: Vol.55(1), Jan-Mar.Description: 205-214p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Indian journal of pharmaceutical education and researchSummary: Background: Clerodendrum is a genus of around 500 species that has a place with the family Lamiaceae. Numerous types of this class have been demonstrated for the treatment of different maladies including cancer. This study aimed to investigate the anti-cancer activity of ethyl acetate fractions of Clerodendrum thomsoniae Balf.f. (EACT) in female Sprague-Dawley rats. Methods: 7, 12-dimethylbenz (a) anthracene (DMBA) was used to induce breast cancer. Two doses of (25 and 50 mg/kg) EACT were used for the study. Various biochemical, hematological and, antioxidant parameters were analyzed. Results: Reduction in mean tumor volume and tumor weight was observed in EACT treated groups. The blood parameters were seen as normal. In both DMBA and doxorubicin groups, malondialdehyde were increased and the level was significantly reduced in EACT-treated groups. The effect of catalase has been seen as reduced in the groups administered by DMBA and doxorubicin and normal in the EACT groups. In the DMBA control groups, nitrate and nitrite were found to increase, the levels in others were normal. There were less necrosis and infiltration in breast tissues treated with doxorubicin as well as in EACT. The curative effect was found to be dose-dependent in animals treated with EACT. Some of the damaged breast patterns were restored to normal by the treatments. GC-MS analysis confirmed 2, 4-bis(1-phenylethyl)-phenol (39%), which was found to be the major compound present in EACT. Conclusion: The study concludes that C. thomsoniae may be a potential anticancer candidate.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2021-2022501 |
Background: Clerodendrum is a genus of around 500 species that has a place with the family Lamiaceae. Numerous types of this class have been demonstrated for the treatment of different maladies including cancer. This study aimed to investigate the anti-cancer activity of ethyl acetate fractions of Clerodendrum thomsoniae Balf.f. (EACT) in female Sprague-Dawley rats. Methods: 7, 12-dimethylbenz (a) anthracene (DMBA) was used to induce breast cancer. Two doses of (25 and 50 mg/kg) EACT were used for the study. Various biochemical, hematological and, antioxidant parameters were analyzed. Results: Reduction in mean tumor volume and tumor weight was observed in EACT treated groups. The blood parameters were seen as normal. In both DMBA and doxorubicin groups, malondialdehyde were increased and the level was significantly reduced in EACT-treated groups. The effect of catalase has been seen as reduced in the groups administered by DMBA and doxorubicin and normal in the EACT groups. In the DMBA control groups, nitrate and nitrite were found to increase, the levels in others were normal. There were less necrosis and infiltration in breast tissues treated with doxorubicin as well as in EACT. The curative effect was found to be dose-dependent in animals treated with EACT. Some of the damaged breast patterns were restored to normal by the treatments. GC-MS analysis confirmed 2, 4-bis(1-phenylethyl)-phenol (39%), which was found to be the major compound present in EACT. Conclusion: The study concludes that C. thomsoniae may be a potential anticancer candidate.
Click on an image to view it in the image viewer
There are no comments for this item.